Katherine E Zychowski1, Bethany Sanchez1, Rodrigo P Pedrosa2, Geraldo Lorenzi-Filho3, Luciano F Drager3, Vsevolod Y Polotsky4, Matthew J Campen5. 1. Department of Pharmaceutical Sciences, University of New Mexico College of Pharmacy, Albuquerque, NM, USA. 2. University of São Paulo Medical School, São Paulo, Brazil; Hospital Metropolitano Sul Dom Helder Câmara - IMIP Hospitalar, Brazil. 3. University of São Paulo Medical School, São Paulo, Brazil. 4. Department of Medicine, Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD, USA. 5. Department of Pharmaceutical Sciences, University of New Mexico College of Pharmacy, Albuquerque, NM, USA. Electronic address: mcampen@salud.unm.edu.
Abstract
BACKGROUND AND AIMS: Obstructive sleep apnea (OSA) is characterized by intermittent airway obstruction and systemic hypoxia during sleep, which can contribute to an increase in reactive oxygen species, vascular remodeling, vasoconstriction and ultimately cardiovascular disease. Continuous positive airway pressure (CPAP) is a clinical therapy that maintains airway patency and mitigates several symptoms of OSA. However, it is currently unknown whether CPAP therapy also reduces the overall inflammatory potential in the circulation; to address this in an unbiased manner, we applied a novel endothelial biosensor approach, the serum cumulative inflammatory potential (SCIP) assay. METHODS: We studied healthy controls (n = 7), OSA subjects receiving no treatment, (OSA controls) (n = 7) and OSA subjects receiving CPAP for 3 months (n = 8). Serum was obtained from OSA subjects before and after CPAP or no treatment. A battery of quantitative and functional assays was performed to assess the serum inflammatory potential, in terms of endothelial responses. For the SCIP assay, human coronary artery endothelial cells (hCAECs) were incubated with 5% serum in media from individual subjects for 4 h. qPCR was performed to assess endothelial inflammatory transcript (ICAM-1, VCAM-1, IL-8, P-selectin, CCL5, and CXCL12) responses to serum. Additionally, transendothelial resistance was measured in serum-incubated hCAECs following leukocyte challenge. RESULTS: hCAECs exhibited significant increases in VCAM-1, ICAM-1, IL-8 and P-selectin mRNA when incubated with serum from OSA patients compared to serum from healthy control subjects. Furthermore, compared to no treatment, serum from CPAP-treated individuals was less potent at inducing inflammatory gene expression in the SCIP assay. Similarly, in a leukocyte adhesion assay, naïve cells treated with serum from patients who received CPAP exhibited improved endothelial barrier function than cells treated with OSA control serum. CONCLUSIONS: OSA results in greater serum inflammatory potential, thereby driving endothelial activation and dysfunction.
BACKGROUND AND AIMS: Obstructive sleep apnea (OSA) is characterized by intermittent airway obstruction and systemic hypoxia during sleep, which can contribute to an increase in reactive oxygen species, vascular remodeling, vasoconstriction and ultimately cardiovascular disease. Continuous positive airway pressure (CPAP) is a clinical therapy that maintains airway patency and mitigates several symptoms of OSA. However, it is currently unknown whether CPAP therapy also reduces the overall inflammatory potential in the circulation; to address this in an unbiased manner, we applied a novel endothelial biosensor approach, the serum cumulative inflammatory potential (SCIP) assay. METHODS: We studied healthy controls (n = 7), OSA subjects receiving no treatment, (OSA controls) (n = 7) and OSA subjects receiving CPAP for 3 months (n = 8). Serum was obtained from OSA subjects before and after CPAP or no treatment. A battery of quantitative and functional assays was performed to assess the serum inflammatory potential, in terms of endothelial responses. For the SCIP assay, human coronary artery endothelial cells (hCAECs) were incubated with 5% serum in media from individual subjects for 4 h. qPCR was performed to assess endothelial inflammatory transcript (ICAM-1, VCAM-1, IL-8, P-selectin, CCL5, and CXCL12) responses to serum. Additionally, transendothelial resistance was measured in serum-incubated hCAECs following leukocyte challenge. RESULTS: hCAECs exhibited significant increases in VCAM-1, ICAM-1, IL-8 and P-selectin mRNA when incubated with serum from OSA patients compared to serum from healthy control subjects. Furthermore, compared to no treatment, serum from CPAP-treated individuals was less potent at inducing inflammatory gene expression in the SCIP assay. Similarly, in a leukocyte adhesion assay, naïve cells treated with serum from patients who received CPAP exhibited improved endothelial barrier function than cells treated with OSA control serum. CONCLUSIONS: OSA results in greater serum inflammatory potential, thereby driving endothelial activation and dysfunction.
Authors: Sanja Jelic; Margherita Padeletti; Steven M Kawut; Christopher Higgins; Stephen M Canfield; Duygu Onat; Paolo C Colombo; Robert C Basner; Phillip Factor; Thierry H LeJemtel Journal: Circulation Date: 2008-04-14 Impact factor: 29.690
Authors: Luciano F Drager; Luiz A Bortolotto; Maria Cecília Lorenzi; Adelaide C Figueiredo; Eduardo M Krieger; Geraldo Lorenzi-Filho Journal: Am J Respir Crit Care Med Date: 2005-05-18 Impact factor: 21.405
Authors: Meghan M Channell; Michael L Paffett; Robert B Devlin; Michael C Madden; Matthew J Campen Journal: Toxicol Sci Date: 2012-02-13 Impact factor: 4.849
Authors: Luciano F Drager; Luzia Diegues-Silva; Patrícia M Diniz; Luiz A Bortolotto; Rodrigo P Pedrosa; Roberta B Couto; Bianca Marcondes; Dante M A Giorgi; Geraldo Lorenzi-Filho; Eduardo M Krieger Journal: Am J Hypertens Date: 2009-12-17 Impact factor: 2.689
Authors: Terri E Weaver; Greg Maislin; David F Dinges; Thomas Bloxham; Charles F P George; Harly Greenberg; Gihan Kader; Mark Mahowald; Joel Younger; Allan I Pack Journal: Sleep Date: 2007-06 Impact factor: 5.849
Authors: Heidi Cung; Mario J Aragon; Katherine Zychowski; Joe R Anderson; James Nawarskas; Carlos Roldan; Akshay Sood; Clifford Qualls; Matthew J Campen Journal: J Transl Med Date: 2015-03-22 Impact factor: 5.531
Authors: Katherine E Zychowski; Abigail Wheeler; Bethany Sanchez; Molly Harmon; Christina R Steadman Tyler; Guy Herbert; Selita N Lucas; Abdul-Mehdi Ali; Sumant Avasarala; Nitesh Kunda; Paul Robinson; Pavan Muttil; Jose M Cerrato; Barry Bleske; Olga Smirnova; Matthew J Campen Journal: Cardiovasc Toxicol Date: 2019-10 Impact factor: 3.231
Authors: Ewa Migacz; Wioletta Olejarz; Alicja Głuszko; Katarzyna Bednarek-Rajewska; Robert Proczka; David F Smith; Stacey L Ishman; Wojciech Kukwa Journal: Diagnostics (Basel) Date: 2021-05-22